 |
|
Effects of Mytatrienediol in Multiple Myeloma, Metastatic Bone Disease, and Osteoporosis
BERNARD KABAKOW, M.D.;
HERTA SPENCER, M.D.
AMA Arch Intern Med. 1960;105(6):905-913.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Multiple myeloma mainly affects the skeleton and may cause marked derangement of mineral metabolism. Hypercalciuria is frequently present and hypercalcemia may be a very serious, and at times fatal, complication of the disease. Estrogens have been shown to decrease urinary calcium excretion 1 and to relieve bone pain in metastatic bone disease2 and in osteoporosis.3,4 In the study of the metabolic effects of newer synthetic hormones, it was found that a weak estrogenic compound, 3-methoxy-16 -methyl-1,3,5 (10)-estratriene-16β, 17β-diol, Mytatrienediol, is effective in decreasing urinary calcium excretion, and the incidental observation of relief of bone pain was made in a patient with multiple myeloma.5 The effect of this hormone was further investigated in a larger number of patients afflicted with this disease, especially in regard to relief of bone pain and to changes of urinary calcium excretion. This hormone was also administered to patients with metastatic bone disease caused
. . . [Full Text PDF of this Article]
Author Affiliations
New York
Division of Neoplastic Diseases, Montefiore Hospital, New York.; Post-Doctoral Research Fellow, National Foundation for Infantile Paralysis, 1957-1958 (Dr. Kabakow).
Footnotes
Submitted for publication Aug. 31, 1959.
Presented at the 49th Annual Meeting of the American Association for Cancer Research, Philadelphia, 1958.
This study was supported by Research Grants A-855 from the National Institutes of Arthritis and Metabolic Diseases and CY-1540 from the National Cancer Institute, United States Public Health Service.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
